Bronte Capital Management Pty Ltd. Cytom X Therapeutics, Inc. Transaction History

Bronte Capital Management Pty Ltd.

  • $1.12 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
SELL
$1.41 - $2.74 $19,393 - $37,685
-13,754 Reduced 1.5%
906,157 $1.98 Million
Q4 2023

Feb 07, 2024
SELL
$1.07 - $1.55 $5,707 - $8,267
-5,334 Reduced 0.58%
919,911 $1.43 Million
Q2 2023

Aug 07, 2023
BUY
$1.41 - $1.92 $10,562 - $14,382
7,491 Added 0.82%
925,245 $1.59 Million
Q1 2023

May 12, 2023
BUY
$1.48 - $2.88 $1.36 Million - $2.64 Million
917,754 New
917,754 $1.39 Million

Others Institutions Holding CTMX

# of Institutions
71
Shares Held
50.7M
Call Options Held
112K
Put Options Held
8.3K
View Full List

About CytomX Therapeutics, Inc.

CTMX Quotes by TradingView
  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $69.9M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Bronte Capital Management Pty Ltd. Portfolio

Follow Bronte Capital Management Pty Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bronte Capital Management Pty Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Bronte Capital Management Pty Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email